Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Phase II study discontinued for vicriviroc in treatment-naive HIV patients

Nov. 2, 2005

TNX-355 reported effective in reducing viral load of HIV-infected patients

Oct. 28, 2005

Aptivus for HIV receives European approval

Oct. 28, 2005

Indevus begins phase III of PRO-2000 to prevent STDs

Oct. 28, 2005

IDO - a target for anti-HIV therapy

Oct. 28, 2005

Enrollment stopped in phase III studies of ONO-4128

Oct. 27, 2005

Novel agents for HIV infection imparted in recent patent literature

Oct. 25, 2005

Maxygen supported in preventative HIV vaccine efforts

Oct. 25, 2005

Positive preclinical results for HIV protease inhibitor PPL-100

Oct. 21, 2005

Novel anti-HIV agents reported in recent patent literature

Oct. 18, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...